ﺑﺮرﺳﯽ ﻣﯿﺰان ﺑﯿﺎن 25-miR در ادرار اﻓﺮاد ﻣﺒﺘﻼ ﺑﻪ ﺳﺮﻃﺎن ﭘﺮوﺳﺘﺎت

Investigation of miR-25 expression in urine of patients with prostate cancer

ﺑﻌﺪ از ﺳﺮﻃﺎن ﭘﺴﺘﺎن، ﺳﺮﻃﺎن ﭘﺮوﺳﺘﺎت ﺷﺎﯾﻊ ﺗﺮﯾﻦ ﺳﺮﻃﺎن ﻣﯽ ﺑﺎﺷﺪ و ﺷﺎﯾﻊ ﺗﺮﯾﻦ ﺳﺮﻃﺎﻧﯽ اﺳﺖ ﮐﻪ ﻣﺮدان ﺑﻪ آن ﻣﺒﺘﻼ ﻣﯽ ﺷﻮﻧﺪ. ﻏﺮﺑﺎﻟﮕﺮي ﺑﺎ ﺑﺮرﺳﯽ ﺳﻄﺢ آﻧﺘﯽ ژن وﯾﮋه ي ﭘﺮوﺳﺘﺎت و اﻧﺠﺎم آزﻣﺎﯾﺸﺎت دﻗﯿﻖ رﮐﺘﺎل ﺗﻮﺻﯿﻪ ﻣﯽ ﺷﻮد، اﻣﺎ ﻫﻨﻮز ﻣﺸﮑﻼﺗﯽ در راﺑﻄﻪ ﺑﺎ اﺧﺘﺼﺎﺻﯿﺖ و ﺣﺴﺎﺳﯿﺖ آزﻣﺎﯾﺸﺎت وﺟﻮد دارد. دﺳﺘﻪ اي از ﺑﯿﻮﻣﺎرﮐﺮﻫﺎي ﺗﺸﺨﯿﺼﯽ، microRNA ﻫﺎ ﻫﺴﺘﻨﺪ ﮐﻪ ﯾﮏ ﮐﻼس از RNA ﻫﺎي ﮐﻮﭼﮏ ﻏﯿﺮ ﮐﺪ ﮐﻨﻨﺪه اﻧﺪ ﮐﻪ ﻧﻘﺶ ﺗﻨﻈﯿﻤﯽ ﮔﺴﺘﺮده اي را در ﻣﺴﯿﺮﻫﺎي ﺳﯿﮕﻨﺎﻟﯿﻨﮓ ﻣﻮﻟﮑﻮﻟﯽ در ﺳﻠﻮل ﺑﺮ ﻋﻬﺪه دارﻧﺪ. ﻫﺪف از اﯾﻦ ﻣﻄﺎﻟﻌﻪ ﺑﺮرﺳﯽ ﺗﻐﯿﯿﺮات ﺳﻄﺢ ﺑﯿﺎن 25-miR در ادرار اﻓﺮاد ﻣﺒﺘﻼ ﺑﻪ ﺳﺮﻃﺎن ﭘﺮوﺳﺘﺎت )ﮔﺮوه ﻣﺘﺎﺳﺘﺎﺗﯿﮏ و ﻏﯿﺮ ﻣﺘﺎﺳﺘﺎﺗﯿﮏ( و اﻓﺮاد ﺳﺎﻟﻢ اﺳﺖ. اﯾﻦ ﭘﮋوﻫﺶ روي 70 ﻧﻤﻮﻧﻪ ادرار اﻓﺮاد ﻣﺒﺘﻼ ﺑﻪ ﺳﺮﻃﺎن ﭘﺮوﺳﺘﺎت )32 ﻧﻔﺮ ﻣﺘﺎﺳﺘﺎﺗﯿﮏ و 38 ﻧﻔﺮ ﻏﯿﺮ ﻣﺘﺎﺳﺘﺎﺗﯿﮏ( و 30 ﻧﻤﻮﻧﻪ ادرار اﻓﺮاد ﺳﺎﻟﻢ ﺑﻪ ﻋﻨﻮان ﮔﺮوه ﮐﻨﺘﺮل، اﻧﺠﺎم ﺷﺪ. اﺳﺘﺨﺮاج RNA ﺑﺎ اﺳﺘﻔﺎده از ﺗﺮاﯾﺰول اﻧﺠﺎم ﺷﺪ و ﭘﺲ از ﺳﻨﺘﺰ cDNA ﺗﻐﯿﯿﺮات ﺳﻄﺢ ﺑﯿﺎن 25-miR در ادرار اﻓﺮاد ﻣﺒﺘﻼ ﺑﻪ ﺳﺮﻃﺎن ﭘﺮوﺳﺘﺎت و اﻓﺮاد ﺳﺎﻟﻢ ﺑﻪ روش qRT-PCRﺑﺮرﺳﯽ ﺷﺪ. آﻧﺎﻟﯿﺰ ﻧﺘﺎﯾﺞ ﺣﺎﺻﻞ ﺑﺎ اﺳﺘﻔﺎده از ﻧﺮم اﻓﺰار REST 2009 اﻧﺠﺎم ﺷﺪ. ﯾﺎﻓﺘﻪ ﻫﺎ ﻧﺸﺎن داد ﮐﻪ 25-miR در اﻓﺮاد ﻣﺒﺘﻼ ﺑﻪ ﺳﺮﻃﺎن ﭘﺮوﺳﺘﺎت در ﻣﻘﺎﯾﺴﻪ ﺑﺎ اﻓﺮاد ﺳﺎﻟﻢ ﮐﺎﻫﺶ ﺑﯿﺎن ﻣﻌﻨﯽ داري )0.001 =P ( دارد. ﻫﻤﭽﻨﯿﻦ 25-miR در ﮔﺮوه ﻣﺘﺎﺳﺘﺎﺗﯿﮏ )0.002 =P ( ﻣﯿﺰان ﺑﯿﺎن ﮐﻤﺘﺮي ﻧﺴﺒﺖ ﺑﻪ ﮔﺮوه ﻏﯿﺮ ﻣﺘﺎﺳﺘﺎﺗﯿﮏ )0.045 =P ( در ﻣﻘﺎﯾﺴﻪ ﺑﺎ اﻓﺮاد ﺳﺎﻟﻢ داﺷﺖ. ﻧﺘﺎﯾﺞ اﯾﻦ ﻣﻄﺎﻟﻌﻪ ﻧﺸﺎن داد ﮐﻪ 25-miR در اﻓﺮاد ﻣﺒﺘﻼ ﺑﻪ ﺳﺮﻃﺎن ﭘﺮوﺳﺘﺎت ﻧﺴﺒﺖ ﺑﻪ اﻓﺮاد ﺳﺎﻟﻢ داراي ﮐﺎﻫﺶ ﺑﯿﺎن ﻣﻌﻨﯽ داري اﺳﺖ. اﻣﯿﺪ اﺳﺖ ﮐﻪ ﺑﺎ ﺗﺤﻘﯿﻘﺎت ﺑﯿﺸﺘﺮ ﺑﺘﻮان ﺑﺎ اﺳﺘﻔﺎده از اﯾﻦ ﺑﯿﻮﻣﺎرﮐﺮ اﻓﺮاد ﻣﺒﺘﻼ ﺑﻪ ﺳﺮﻃﺎن ﭘﺮوﺳﺘﺎت را ﺑﺎ ﺳﺮﻋﺖ و دﻗﺖ ﺑﯿﺸﺘﺮي ﺗﺸﺨﯿﺺ داد.

Prostate cancer is the most common cancer in men. Screening is recommended by examining prostate-specific antigen (PSA) levels and performing accurate rectal tests, but there are still problems with the specificity and sensitivity of these tests. A group of diagnostic biomarkers are microRNAs, a class of small non-coding RNAs that play a broad regulatory role in molecular signaling pathways in the cell. The aim of this study was to investigate the changes in the expression level of miR-25 in the urine of patients with prostate cancer (metastatic and non-metastatic groups) and healthy individuals. samples from prostate cancer patients (32 metastatic and 38 non metastatic) and 30 from healthy subjects with negative biopsy reports were collected. RNA was extracted with Trizol and cDNA was synthesized with PARSGENOME MiR-Amp Kit. The expression level of miR-25 in the urine was detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Statistical analysis of data was calculated with REST 2009. The results showed that miR-25 significantly reduced expression in patients with prostate cancer compared to healthy individuals (P = 0.001). Also, miR-25 in the metastatic group (P = 0.002) had a lower expression than the non-metastatic group (P = 0.045) compared to healthy individuals. The results of this study showed that miR-25 had a significant decrease expression in patients with prostate cancer compared to healthy individuals. It is hoped that more research will be able to use this marker to diagnose prostate cancer more quickly and accurately.